It is reported that Slit2, as a potent lymphangiogenic factor, contributes to tumor lymphatic metastasis [57]; VEGF-A treated lymphatic endothelial cell exhibited STAT3 activation in the nucleus, thereby enhancing lymphatic endothelial cell migration and increased tube formation (63). Here, SLIT2 is linked to neoplasm.